carnitine has been researched along with Muscle Contraction in 38 studies
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| "l-Carnitine pretreatment significantly increased tetanic contraction amplitude in the SOL muscles following I/R (P < ." | 5.39 | L-carnitine pretreatment protects slow-twitch skeletal muscles in a rat model of ischemia-reperfusion injury. ( Cerkez, C; Demirel, M; Ertunc, M; Kaya, B; Sara, Y, 2013) |
| " Plasma levels of glucose, insulin, malondialdehyde and antioxidants such as reduced glutathione, catalase and superoxide dismutase, haemoglobin A1c (HbA1c), insulin sensitivity index (ISI) as well as the contractile properties of the gastrocnemius muscle were measured." | 3.88 | Effect of L-carnitine on diabetes-induced changes of skeletal muscles in rats. ( Abbas, AM; Elserougy, HG; Safwat, SM; Samir, SM, 2018) |
| "The carnitine group was administered levo-carnitine 200 mg/kg/day intraperitoneally for 6 days." | 2.78 | Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 diabetic rats. ( Bin Aleem, S; Farooq, Y; Hussain, MM, 2013) |
| "Carnitine is an endogenous compound with well-established roles in intermediary metabolism." | 2.41 | Supplemental carnitine and exercise. ( Brass, EP, 2000) |
| "Carnitine depletion was associated with a 30% decrease soleus muscle weight, whereas contractile function (expressed per gram of muscle), free coenzyme A, and water content remained unaltered from CON." | 1.42 | Contractile function and energy metabolism of skeletal muscle in rats with secondary carnitine deficiency. ( Bonifacio, A; Bouitbir, J; Kaufmann, P; Krähenbühl, S; Roberts, PA; Singh, F; Urwyler, A, 2015) |
| "l-Carnitine pretreatment significantly increased tetanic contraction amplitude in the SOL muscles following I/R (P < ." | 1.39 | L-carnitine pretreatment protects slow-twitch skeletal muscles in a rat model of ischemia-reperfusion injury. ( Cerkez, C; Demirel, M; Ertunc, M; Kaya, B; Sara, Y, 2013) |
| "L-carnitine treatment restored the hyporesponsiveness of isoprenaline and the hyperresponsiveness of adenosine-elicited relaxation." | 1.35 | L-carnitine treatment partially restores urinary bladder function of streptozotocin diabetic rats. ( Gur, S; Irat, AM, 2008) |
| " We concluded that weekly short-term stimulation does not lead to a change in fiber type; however, carnitine combined with minimal stimulation of the muscle leads to a significant shift in muscle fiber type composition toward a muscle with an increased content of type I fibers." | 1.29 | L-carnitine combined with minimal electrical stimulation promotes type transformation of canine latissimus dorsi. ( De Jong, YF; Dubelaar, ML; Glatz, JF; Hülsmann, WC; Van der Veen, FH, 1994) |
| "Carnitine has been used to enhance human exercise performance." | 1.29 | Carnitine delays rat skeletal muscle fatigue in vitro. ( Brass, EP; Masterson, KA; Ruff, LJ; Scarrow, AM; Van Lunteren, E, 1993) |
| "L-acetylcarnitine-treated animals show significantly higher twitch and tetanic tensions of re-innervated muscle." | 1.28 | L-acetylcarnitine enhances functional muscle re-innervation. ( Brunetti, O; Carobi, C; Della Torre, G; Grassi, S; Pettorossi, VE, 1991) |
| "The effects of chronic administration of L-carnitine were evaluated by EMG analysis in 20 uraemic patients undergoing periodical haemodialysis (mean duration of dialysis 34." | 1.27 | Effects of carnitine administration in patients with chronic renal failure undergoing periodic dialysis, evaluated by computerized electromyography. ( Alfarone, C; Calvani, M; D'Iddio, S; Feola, I; Frascarelli, M; Rocchi, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (23.68) | 18.7374 |
| 1990's | 11 (28.95) | 18.2507 |
| 2000's | 6 (15.79) | 29.6817 |
| 2010's | 11 (28.95) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Adebayo, AS | 1 |
| Roman, M | 1 |
| Zakkar, M | 1 |
| Yusoff, S | 1 |
| Gulston, M | 1 |
| Joel-David, L | 1 |
| Anthony, B | 1 |
| Lai, FY | 1 |
| Murgia, A | 1 |
| Eagle-Hemming, B | 1 |
| Sheikh, S | 1 |
| Kumar, T | 1 |
| Aujla, H | 1 |
| Dott, W | 1 |
| Griffin, JL | 1 |
| Murphy, GJ | 1 |
| Woźniak, MJ | 1 |
| Yang, X | 1 |
| Rodriguez, ML | 1 |
| Leonard, A | 1 |
| Sun, L | 1 |
| Fischer, KA | 1 |
| Wang, Y | 1 |
| Ritterhoff, J | 1 |
| Zhao, L | 1 |
| Kolwicz, SC | 1 |
| Pabon, L | 1 |
| Reinecke, H | 1 |
| Sniadecki, NJ | 1 |
| Tian, R | 1 |
| Ruohola-Baker, H | 1 |
| Xu, H | 1 |
| Murry, CE | 1 |
| Samir, SM | 1 |
| Abbas, AM | 1 |
| Safwat, SM | 1 |
| Elserougy, HG | 1 |
| Ghalwash, M | 1 |
| Elmasry, A | 1 |
| El-Adeeb, N | 1 |
| Demirel, M | 1 |
| Kaya, B | 1 |
| Cerkez, C | 1 |
| Ertunc, M | 1 |
| Sara, Y | 1 |
| Furuichi, Y | 2 |
| Goto-Inoue, N | 1 |
| Manabe, Y | 1 |
| Setou, M | 1 |
| Masuda, K | 2 |
| Fujii, NL | 1 |
| Ciapaite, J | 1 |
| van den Berg, SA | 1 |
| Houten, SM | 1 |
| Nicolay, K | 1 |
| van Dijk, KW | 1 |
| Jeneson, JA | 1 |
| Roberts, PA | 2 |
| Bouitbir, J | 1 |
| Bonifacio, A | 1 |
| Singh, F | 1 |
| Kaufmann, P | 1 |
| Urwyler, A | 1 |
| Krähenbühl, S | 1 |
| Ruiz, M | 1 |
| Coderre, L | 1 |
| Lachance, D | 1 |
| Houde, V | 1 |
| Martel, C | 1 |
| Thompson Legault, J | 1 |
| Gillis, MA | 1 |
| Bouchard, B | 1 |
| Daneault, C | 1 |
| Carpentier, AC | 1 |
| Gaestel, M | 1 |
| Allen, BG | 1 |
| Des Rosiers, C | 1 |
| Dutta, A | 1 |
| Ray, K | 1 |
| Singh, VK | 1 |
| Vats, P | 1 |
| Singh, SN | 1 |
| Singh, SB | 1 |
| Gur, S | 1 |
| Irat, AM | 1 |
| Thyfault, JP | 1 |
| Cree, MG | 1 |
| Tapscott, EB | 1 |
| Bell, JA | 1 |
| Koves, TR | 1 |
| Ilkayeva, O | 1 |
| Wolfe, RR | 1 |
| Dohm, GL | 1 |
| Muoio, DM | 1 |
| Sugiura, T | 1 |
| Kato, Y | 1 |
| Takakura, H | 1 |
| Hanai, Y | 1 |
| Hashimoto, T | 1 |
| Bin Aleem, S | 1 |
| Hussain, MM | 1 |
| Farooq, Y | 1 |
| Uzuner, N | 1 |
| Kavukcu, S | 1 |
| Karaman, O | 1 |
| Apaydin, S | 1 |
| Göldeli, E | 1 |
| Loxham, SJ | 1 |
| Poucher, SM | 2 |
| Constantin-Teodosiu, D | 2 |
| Greenhaff, PL | 2 |
| Lopes, G | 1 |
| Bazotte, RB | 1 |
| Curi, R | 1 |
| Alves-Do-Prado, W | 1 |
| Carter, AL | 1 |
| Lennon, DL | 1 |
| Stratman, FW | 1 |
| Giovenali, P | 1 |
| Fenocchio, D | 1 |
| Montanari, G | 1 |
| Cancellotti, C | 1 |
| D'Iddio, S | 2 |
| Buoncristiani, U | 1 |
| Pelagaggia, M | 1 |
| Ribacchi, R | 1 |
| Dubelaar, ML | 2 |
| Glatz, JF | 1 |
| De Jong, YF | 1 |
| Van der Veen, FH | 1 |
| Hülsmann, WC | 2 |
| Brass, EP | 2 |
| Scarrow, AM | 1 |
| Ruff, LJ | 1 |
| Masterson, KA | 1 |
| Van Lunteren, E | 1 |
| Mancinelli, R | 1 |
| Pierrefiche, G | 1 |
| Reynier, M | 1 |
| Laborit, H | 1 |
| Timmons, JA | 1 |
| Worrall, V | 1 |
| Macdonald, IA | 1 |
| Alkonyi, I | 1 |
| Kerner, J | 1 |
| Sándor, A | 1 |
| Dainty, IA | 1 |
| Bigaud, M | 1 |
| McGrath, JC | 1 |
| Spedding, M | 1 |
| Spencer, MK | 1 |
| Yan, Z | 1 |
| Katz, A | 1 |
| Pettorossi, VE | 1 |
| Brunetti, O | 1 |
| Carobi, C | 1 |
| Della Torre, G | 1 |
| Grassi, S | 1 |
| Lucas, CM | 1 |
| Siami, G | 1 |
| Clinton, ME | 1 |
| Mrak, R | 1 |
| Griffis, J | 1 |
| Stone, W | 1 |
| Bettini, V | 2 |
| Catozzo, C | 1 |
| Martino, R | 2 |
| Mayellaro, F | 1 |
| Munari, L | 1 |
| Tegazzin, V | 1 |
| Ton, P | 2 |
| Sahgal, V | 1 |
| Solomon, R | 1 |
| Harris, RC | 1 |
| Foster, CV | 1 |
| Hultman, E | 1 |
| Norani, M | 1 |
| Legrenzi, E | 1 |
| Rocchi, L | 1 |
| Feola, I | 1 |
| Calvani, M | 1 |
| Alfarone, C | 1 |
| Frascarelli, M | 1 |
| Blum, K | 1 |
| Seifter, E | 1 |
| Seifter, J | 1 |
| Baldwin, KM | 1 |
| Tipton, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Observational Case Control Study to Identify the Role of Epigenetic Regulation of Genes Responsible for Energy Metabolism and Mitochondrial Function in the Obesity Paradox in Cardiac Surgery[NCT02908009] | 80 participants (Anticipated) | Observational | 2016-09-09 | Recruiting | |||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
1 review available for carnitine and Muscle Contraction
| Article | Year |
|---|---|
Supplemental carnitine and exercise.
Topics: Carnitine; Coenzyme A; Dietary Supplements; Exercise; Fatty Acids; Female; Humans; Male; Muscle Cont | 2000 |
Supplemental carnitine and exercise.
Topics: Carnitine; Coenzyme A; Dietary Supplements; Exercise; Fatty Acids; Female; Humans; Male; Muscle Cont | 2000 |
Supplemental carnitine and exercise.
Topics: Carnitine; Coenzyme A; Dietary Supplements; Exercise; Fatty Acids; Female; Humans; Male; Muscle Cont | 2000 |
Supplemental carnitine and exercise.
Topics: Carnitine; Coenzyme A; Dietary Supplements; Exercise; Fatty Acids; Female; Humans; Male; Muscle Cont | 2000 |
2 trials available for carnitine and Muscle Contraction
| Article | Year |
|---|---|
Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 diabetic rats.
Topics: Animals; Carnitine; Diabetes Mellitus, Type 2; Malondialdehyde; Muscle Contraction; Muscle Fatigue; | 2013 |
Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis.
Topics: Carnitine; Double-Blind Method; Fatty Acids; Humans; Injections, Intravenous; Kidney Failure, Chroni | 1991 |
35 other studies available for carnitine and Muscle Contraction
| Article | Year |
|---|---|
Gene and metabolite expression dependence on body mass index in human myocardium.
Topics: Aged; Aged, 80 and over; Body Mass Index; Carnitine; Case-Control Studies; Cholesterol; Cohort Studi | 2022 |
Fatty Acids Enhance the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
Topics: Calcium; Carnitine; Cell Differentiation; Cell Line; Dietary Supplements; Fatty Acids; Humans; Induc | 2019 |
Effect of L-carnitine on diabetes-induced changes of skeletal muscles in rats.
Topics: Animals; Antioxidants; Carnitine; Catalase; Diabetes Mellitus, Experimental; Glucose; Glutathione; G | 2018 |
Effect of L-carnitine on the skeletal muscle contractility in simvastatin-induced myopathy in rats.
Topics: Animals; Carnitine; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Cont | 2018 |
L-carnitine pretreatment protects slow-twitch skeletal muscles in a rat model of ischemia-reperfusion injury.
Topics: Animals; Carnitine; Cytoprotection; Disease Models, Animal; Electric Stimulation; Male; Muscle Contr | 2013 |
Imaging mass spectrometry reveals fiber-specific distribution of acetylcarnitine and contraction-induced carnitine dynamics in rat skeletal muscles.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Carnitine; Male; Muscle Contraction; Muscle, Skele | 2014 |
Fiber-type-specific sensitivities and phenotypic adaptations to dietary fat overload differentially impact fast- versus slow-twitch muscle contractile function in C57BL/6J mice.
Topics: Acyl-CoA Dehydrogenase; Allostasis; Animals; Carnitine; Diet, Fat-Restricted; Diet, High-Fat; Electr | 2015 |
Contractile function and energy metabolism of skeletal muscle in rats with secondary carnitine deficiency.
Topics: Animals; Apoptosis; Biomarkers; Carnitine; Deficiency Diseases; Disease Models, Animal; Energy Metab | 2015 |
MK2 Deletion in Mice Prevents Diabetes-Induced Perturbations in Lipid Metabolism and Cardiac Dysfunction.
Topics: Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fatty Acids, Noneste | 2016 |
L-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats.
Topics: Animals; Carnitine; Creatine Kinase, MM Form; Glutathione; Hypoxia; Lipid Peroxides; Male; Muscle Co | 2008 |
L-carnitine treatment partially restores urinary bladder function of streptozotocin diabetic rats.
Topics: Adenosine; Adenosine Triphosphate; Adrenergic beta-Agonists; Animals; Autonomic Nervous System; Bloo | 2008 |
Metabolic profiling of muscle contraction in lean compared with obese rodents.
Topics: Acetyl-CoA Carboxylase; Animals; Biological Transport; Carnitine; Glucose; Glycogen; Lactic Acid; Li | 2010 |
Muscle contraction increases carnitine uptake via translocation of OCTN2.
Topics: Animals; Biological Transport; Carnitine; Male; Muscle Contraction; Muscle, Skeletal; Organic Cation | 2012 |
L-carnitine does not exert any in vitro relaxant effect in Guinea pig trachea, lung parenchyma and human bronchial tissue.
Topics: Animals; Bronchi; Carbachol; Carnitine; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; Hu | 2002 |
The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle.
Topics: Acetyl Coenzyme A; Acetylation; Animals; Carnitine; Coenzyme A; Dogs; Enzyme Activation; In Vitro Te | 2002 |
L- and DL-carnitine induce tetanic fade in rat neuromuscular preparation.
Topics: Animals; Carnitine; Diaphragm; Electric Stimulation; Male; Muscle Contraction; Phrenic Nerve; Rats; | 2003 |
Increased acetyl carnitine in rat skeletal muscle as a result of high-intensity short-duration exercise. Implications in the control of pyruvate dehydrogenase activity.
Topics: Acetyl Coenzyme A; Acetylcarnitine; Animals; Carnitine; Carnitine O-Acetyltransferase; Male; Muscle | 1981 |
Selective trophic effect of L-carnitine in type I and IIa skeletal muscle fibers.
Topics: Carnitine; Energy Metabolism; Female; Humans; Hypertrophy; Male; Middle Aged; Muscle Contraction; Mu | 1994 |
L-carnitine combined with minimal electrical stimulation promotes type transformation of canine latissimus dorsi.
Topics: Animals; Body Composition; Carnitine; Dogs; Electric Stimulation; Electrodes, Implanted; Electron Tr | 1994 |
Carnitine delays rat skeletal muscle fatigue in vitro.
Topics: Animals; Carnitine; Electric Stimulation; Glycogen; In Vitro Techniques; Kinetics; Lactates; Lactic | 1993 |
L-propionylcarnitine and synchronization of spontaneous activity in rat isolated portal vein.
Topics: Animals; Cardiotonic Agents; Carnitine; Electrophysiology; Extracellular Space; In Vitro Techniques; | 1993 |
Carnitine action on neuromuscular disturbances in the fasting rat: potentiation by L-lysine.
Topics: Administration, Oral; Animals; Carnitine; Drug Synergism; Fasting; Fatty Acids; Lysine; Male; Mitoch | 1993 |
Increased acetyl group availability enhances contractile function of canine skeletal muscle during ischemia.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aerobiosis; Anaerobiosis; Animals; Carbohydrate Metabolism; | 1996 |
The possible role of carnitine and carnitine acetyl-transferase in the contracting frog skeletal muscle.
Topics: Acetyltransferases; Animals; Carnitine; Electric Stimulation; Muscle Contraction; Muscles; Pyruvates | 1975 |
Interactions of palmitoyl carnitine with the endothelium in rat aorta.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1990 |
Carbohydrate supplementation attenuates IMP accumulation in human muscle during prolonged exercise.
Topics: Adult; Blood Glucose; Carnitine; Dietary Carbohydrates; Fatty Acids; Female; Glycogen; Heart Rate; H | 1991 |
L-acetylcarnitine enhances functional muscle re-innervation.
Topics: Acetylcarnitine; Animals; Carnitine; Male; Muscle Contraction; Muscle Denervation; Muscle Relaxation | 1991 |
Acute effect of L-carnitine on skeletal muscle force tests in dogs.
Topics: Blood Glucose; Carnitine; Choline; Electric Stimulation; Exercise; Fatty Acids, Nonesterified; Insul | 1991 |
[Changes in acetylcholine contractions induced by carnitine in coronary vessels isolated "in vitro"].
Topics: Acetylcholine; Animals; Atropine; Calcium; Carnitine; Cattle; Coronary Vessels; Fendiline; In Vitro | 1985 |
Metabolic response to exercise and muscle disease.
Topics: Adenosine Triphosphatases; Calcium; Carnitine; Carnitine O-Palmitoyltransferase; Female; Glycogen; G | 1986 |
Acetylcarnitine formation during intense muscular contraction in humans.
Topics: Acetylcarnitine; Adult; Carnitine; Electric Stimulation; Humans; Kinetics; Male; Muscle Contraction; | 1987 |
[Cholinomimetics effects of carnitine on isolated and denervated rat stomach preparations].
Topics: Animals; Carnitine; Denervation; In Vitro Techniques; Muscle Contraction; Muscle, Smooth; Parasympat | 1986 |
Effects of carnitine administration in patients with chronic renal failure undergoing periodic dialysis, evaluated by computerized electromyography.
Topics: Adult; Carnitine; Computers; Electromyography; Evoked Potentials; Female; Humans; Kidney Failure, Ch | 1986 |
The pharmacology of d- and l-carnitine and d- and l-acetylcarnitine. Comparison with choline and acetylcholine.
Topics: Acetates; Acetylcholine; Animals; Anura; Blood Pressure; Brain; Carnitine; Cats; Chickens; Choline; | 1971 |
Work and metabolic patterns of fast and slow twitch skeletal muscle contracting in situ.
Topics: Acyltransferases; Animals; Carnitine; Fatty Acids; Glycogen; Hindlimb; Lactates; Male; Methods; Musc | 1972 |